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Background:Calreticulin (CRT) retrotranslocated from the endoplasmic reticulum to the cytoplasm is post-translationally
arginylated.
Results:ArginylatedCRT (R-CRT) has a longer half-life than non-arginylatedCRTanddisplays different ubiquitin dependence.
Conclusion: CRT and R-CRT differ in their susceptibility to proteasomal degradation.
Significance: Arginylation is not required for proteasomal degradation of CRT, although R-CRT displays ubiquitin
modification.
Post-translational arginylation has been suggested to target
proteins for proteasomal degradation. The degradation mecha-
nism for arginylated calreticulin (R-CRT) localized in the cyto-
plasm is unknown. To evaluate the effect of arginylation onCRT
stability, we examined the metabolic fates and degradation
mechanisms of cytoplasmic CRT and R-CRT in NIH 3T3 and
CHO cells. Both CRT isoforms were found to be proteasomal
substrates, but the half-life of R-CRT (2 h) was longer than that
of cytoplasmic CRT (0.7 h). Arginylation was not required for
proteasomal degradation of CRT, although R-CRT displays
ubiquitin modification. A CRT mutant incapable of dimeriza-
tion showed reduced metabolic stability of R-CRT, indicating
that R-CRT dimerization may protect it from proteasomal deg-
radation. Our findings, taken together, demonstrate a novel
function of arginylation: increasing the half-life of CRT in
cytoplasm.
Post-translational modifications (PTMs)3 of proteins are
essential for regulation of subcellular localization, function,
structure, and complex formation capability (1–3). Arginyla-
tion is a PTM mediated by arginyl-tRNA-protein transferase
(Ate1), which transfers Arg from arginyl-tRNA onto proteins
that have an acidic amino acid or Cys as the N-terminal residue
(4–6). Many proteins are arginylated in vivo (7, 8), and this
PTM plays key roles in a variety of physiological processes (3)
including cell adhesion (9, 10), apoptosis (11), and cellular
stress (7, 12, 13).
Calreticulin (CRT) is localized mainly in the endoplasmic
reticulum (ER) and has multiple functions within and outside
the ER (14–16). Our group was the first to demonstrate the
retrotranslocation of CRT from the ER (ER-CRT) to the cyto-
plasm under conditions that promote reduction of cytoplasmic
Ca2 levels (7, 12). In the cytoplasm, CRT is post-translation-
ally arginylated in vivo by Ate1 (7, 12). Arginylated CRT
(R-CRT) is not detectable in the ER lumen (7), consistently with
the cytosolic and nuclear localization of Ate1 (17). We showed
that arginylation of CRT is essential for its association with
stress granules (SGs) and promotes its dimerization (7, 13).
Apoptosis induction is associated with an increased R-CRT
level at the cell surface (11). Surface exposure of CRT on tumor
cells has been suggested to promote their uptake by phagocytes
(18). The effects of CRT arginylation on its cytoplasmic func-
tions and final destination remain to be elucidated.
According to the “N-end rule,” which relates the half-life of a
protein to the identity of its N-terminal residue, N-terminal
Asp and Glu are secondary destabilizing residues that function
through their arginylation to yield the primary destabilizing
residue Arg (19). Arginylation in turn promotes protein recog-
nition by specific E3 ubiquitin (Ub)-protein ligases that polyu-
biquitinate proteins on internal Lys residues (20). Proteasomal
degradation depends in most cases on Ub conjugation (ubiq-
uitination). However, a significant subset of proteins displays
ubiquitination-independent turnover (21), which is not sur-
prising in view of the co-existence of several types of protea-
somal complexes in eukaryotic cells (22). The possible role of
CRT as a substrate for proteasomal degradation is controversial
(23–25). The degradation mechanism of R-CRT remains
unknown.
To assess the effect of CRT arginylation on its stability, we
studied the degradation of cytoplasmic CRT (cyt-CRT) and
R-CRT in fibroblasts and CHO cells, including the roles of pro-
teasomes, Ub modification, and dimer formation in this pro-
cess. We found that arginylated and non-arginylated isoforms
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of CRT are proteasomal substrates that follow different degra-
dation pathways: one dependent on and the other independent
of Ub modification. Biochemical analysis showed that CRT
arginylation leads to ubiquitination of R-CRT isoforms but
reduces turnover rate. Our finding that arginylation stabilizes
CRT is in contrast to the traditional view of arginylation as a
destabilizing factor.
Experimental Procedures
Cell Culture—All cell lines were cultured in a humidified
incubator with 5%CO2 in standardDMEM (Life Technologies)
supplemented with 10% (v/v) FBS (Life Technologies), 4 mM
L-glutamine (Sigma), 200 units/ml penicillin, and 100 g/ml
streptomycin (Life Technologies). ATE1/ and ATE1/
mouse EF (embryonic fibroblast) cell lines were kindly provided
by Dr. A. Kashina (Dept. of Animal Biology/Biochemistry,
University of Pennsylvania, Philadelphia, PA). CRT/ and
CRT/ mouse EF cell lines were a gift from Dr. M. Michalak
(Dept. of Biochemistry, University of Alberta, Edmonton,
Canada).
Plasmids—For cloning of pEGFP-CRT (with signal peptide)
we digested pEYFP-CRT plasmid (12) with EcoRI and KpnI
endonucleases and cloned the fragment containing the coding
sequence of human full-lengthCRT into pEGFP-N1 expression
vector (Clontech Laboratories; Palo Alto, CA). To express
mature CRT (without signal peptide) in cytoplasm, we adapted
a strategy described previously for GFP (26). In brief, DNAs
encodingUb fused tomature humanCRT (Ub-CRT) or R-CRT
(Ub-R-CRT) were cloned in pEGFP-N1 expression vector. The
Ub moiety was cleaved in cytoplasm by Ub-C-terminal hydro-
lases to release mature CRT with exposed N-terminal Glu or
Arg, as confirmed by Western blotting (Fig. 3). For cloning of
pEGFP-Ub-CRT and pEGFP-Ub-R-CRT cDNAs, the coding
sequences of Ub-CRT and R-CRT were amplified by PCR from
pHUE-CRT-FLAG and pHUE-R-CRT-FLAG expression vec-
tors, respectively (11). The forward primer (same for both
amplification reactions) contained an EcoRI restriction site
(underlined), a Kozak sequence (boldfaced), and the Ub
sequence (italicized): 5-CCGGAATTCCCCGCCGCCACC-
ATGCAGATCTTTGTGAAGACCCTCACTGG-3. The reverse
primer (the same for both amplification reactions) contained a
KpnI restriction site (underlined) and the CRT sequence (itali-
cized): 5-CGGGGTACCCCCAGCTCGTCCTTGGCCTG
GCC-3. The PCR products were digested with EcoRI and KpnI
endonucleases and cloned into pEGFP-N1 expression vector.
All constructs were confirmed by DNA sequencing.
Mutant Construction and Site-directed Mutagenesis—For
generation of the pEGFP-C146A-CRTmutant, we digested the
pEYFP-C146A-CRT plasmid (13) with EcoRI and KpnI endo-
nucleases and cloned the fragment containing the coding
sequence of human full-length C146A-CRT into pEGFP-N1
expression vector.
For cloning of the pEGFP-Ub-E1V-CRTmutant, we used the
site-specific mutagenesis method with overlap extension (27).
Construction of the E1V mutation (numbering starts from the
mature CRT) required two mutagenic primers, two flanking
oligonucleotides, and three PCR. One pair of primers was used
to amplify the DNA containing the mutation site together with
downstream sequences. The reverse primer contained the
mutation (underlined and boldfaced) introduced into the wild-
type (WT) template cDNA of Ub-CRT: 5-AAGTAGACGGC-
AGGCACTCCACCGCGGAGGCGCAACACC-3. The for-
ward primer (F2) was the same as for the Ub-CRTWT sequence
described under “Plasmids” (above) and contained an EcoRI re-
striction site, a Kozak sequence, and the Ub sequence. The sec-
ond pair of primers was used to amplify the DNA that con-
tained the mutation site together with upstream sequences.
The forward primer of this pair contained themutation (under-
lined and boldfaced) introduced into the template DNA and
was complementary to reverse primer: 5-GCCTCCGCGGT-
GGAGTGCCTGCCGTCTACTTCAAGGAGC-3. The reverse
primer (R2) was the same as for the Ub-CRT WT sequence
described under “Plasmids” (above) and contained a KpnI re-
striction site and theCRT sequence. To amplify the overlapping
DNA fragments, both sets of primers were used in two separate
amplification reactions. Themutation of interest was located in
the overlap region and, therefore, in both sets of the resulting
amplified fragments. The full-length Ub-E1V-CRT DNA was
amplified by a third PCR,mixing the overlapping fragments and
using primers F2 and R2 that bind to the 3 and 5 extremes of
the initial fragments, respectively. The PCR products were
digested with EcoRI and KpnI endonucleases and cloned into
pEGFP-N1 expression vector. All constructswere confirmedby
DNA sequencing.
Cell Transfection—CHO cells were transfected using Lipo-
fectamine 2000 and Opti-MEM (Life Technologies) according
to themanufacturer’s instructions. ATE1/ andCRT/ cells
were transfected in Opti-MEM with pEGFP-Ub-CRT or
pEGFP-Ub-R-CRT and pEGFP-CRT or pEGFP-C146A-CRT,
respectively, using Lipofectamine LTX with Plus reagent (Life
Technologies).
Inhibitor Treatments—Inhibitors (Sigma) were used at the
following concentrations:MG132 10M, cycloheximide (CHX)
50 g/ml, thapsigargin (Tg) 2 M.
Establishment of Stable Cell Lines—CHO cells were trans-
fected with pEGFP-Ub-CRT, pEGFP-Ub-R-CRT, or pEGFP-
Ub-E1V-CRT. Stably transfected cell lines were selected in the
presence of 0.5 mg/ml G418 (Phytotechnology Laboratories;
Overland Park, KS). To obtain stable cell lines that uniformly
expressed CRT-EGFP, R-CRT-EGFP, or E1V-CRT-EGFP, we
isolated populations with intermediate levels of EGFP expres-
sion by fluorescence-activated cell sorting (FACS Aria IIu; BD
Biosciences) after treatment with MG132 (Sigma).
Immunofluorescence—Cells were grown on glass coverslips
to 60% confluence, and immunofluorescence was stimulated as
described previously (7, 13). Nuclei were stained with DAPI.
Protein Half-life Assay—Stable CHO cell lines expressing
CRT-EGFP, R-CRT-EGFP, or E1V-CRT-EGFPwere treated for
9 h with MG132 to cause accumulation of EGFP fusion pro-
teins. Alternatively, ATE1/ cells were transfected transiently
with pEGFP-Ub-CRT or pEGFP-Ub-R-CRT, cultured for 6 h,
and treated with MG132 for the indicated times in the Figs. 8
and 9 legends. In both cases cells were washed 4 times, cultured
for 1 h to allow diffusion of the inhibitor, and washed again.
CHO cells were incubated for various durations with CHX or
MG132. Proteins were separated by SDS-PAGE, and levels of
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EGFP fusion proteins and R-CRT were monitored by Western
blotting.
In Vivo Ubiquitination Assay—To increase Ub levels and the
sensitivity ofUbdetection, CHOcells were transfected transiently
with pcDNA3-HA-Ub or co-transfected with pcDNA3-HA-Ub
andpEGFP-Ub-R-CRTor pEGFP-Ub-E1V-CRT. Six hours after
transfection, cells were cultured with proteasome inhibitor for
16–18 h. Cell lysates were prepared using lysis buffer (50 mM
Tris-HCl, pH 7.5, 150 mMNaCl, 1% Nonidet P-40, 0.1% deoxy-
cholate) plus 5 mM iodoacetamide, 5 mMN-ethylmaleimide, 10
MMG132, and 1:100 protease inhibitormixture (Calbiochem)
to inhibit deubiquitinating enzymes and proteases and then
sonicated briefly on ice. The remaining stepswere performed at
4 °C. Lysateswere precleared by centrifugation at 13,000 g for
10 min, and the supernatants were subjected to immunopre-
cipitation for EGFP. The protein samples were separated by
SDS-PAGE and immunoblotting with anti-HA and anti-GFP
antibodies (Abs).
Immunoprecipitation—All stepswere performed at 4 °C. Cell
lysateswere incubated on an orbital shakerwith 50l of protein
G-Sepharose beads (GE Healthcare) for 2 h to reduce nonspe-
cific protein binding. Beads were pelleted for 20 s at 2300 rpm.
To immunoprecipitate EGFP fusion proteins, supernatants
were incubated with 2 l of anti-GFP for 1 h, added with 50 l
of protein G-Sepharose beads, and incubated on a rocker for
4 h. Protein G-SepharoseAb complexes were pelleted at 2300
rpm for 20 s and washed twice in 500l of lysis buffer and once
in washing buffer (50mMTris-HCl, pH 7.5, 250mMNaCl, 0.1%
Nonidet P-40, 0.05% deoxycholate). Protein G-SepharoseAb
complexes were resuspended in sample buffer 2. Total cell
lysate and bound and unbound fractions were subjected to
SDS-PAGE, and proteins were transferred to nitrocellulose
membrane for immunoblotting.
Cell Viability Assay—Cell viability was determined by the
colorimetric technique using resazurin (28) (Sigma). In each
assay, 10,000 cells were plated per well in 96-well plates. Cells
were treated at various intervals (see Fig. 6A) with 10 M
MG132 or vehicle. After this treatment, 2 l of 1 mg/ml resaz-
urin solution were added to 200 ml of medium per well. Plates
were incubated at 37 °C for 4 h, and the optical density was
measured at 600 nm wavelength in a FL X800 Microplate
Reader (BioTek Instruments, Inc.)
Assessment of Cell Death—Cells/sample were collected as in
López Sambrooks et al. (11). Briefly, cells were washed in PBS,
pelleted, and resuspended in buffer (10 mMHEPES/NaOH, pH
7.4, 140 mM NaCl, 2.5 mM CaCl2) containing propidium iodide
to identify dead cells. Cells were analyzed by flow cytometry on
a FACSCantoII cytometer (BD Biosciences) using FlowJo
software.
Western Blotting—Proteins from cell lysates and immuno-
precipitates were resolved by SDS-PAGE (29) and transferred
onto nitrocellulosemembranes (Potran BA 83,Whatman; San-
ford, FL) (30). The filters were blocked at room temperature for
1 h in PBS supplemented with 5% nonfat dry milk. Blots were
incubated with primary Abs to detect the expression of EGFP
(1:2,500, mouse monoclonal anti-GFP Ab, Roche Applied Sci-
ence), R-CRT (1:100, rabbit anti-R-CRT polyclonal antibody
(pAb), custom made by Eurogentec; Seraing, Belgium) (7, 12),
-actin (1:20,000, mouse monoclonal anti--actin Ab; Sigma),
and HA-Ub (1:1,500, rabbit monoclonal anti-HA Ab, Cell Sig-
naling; Boston, MA)) overnight on a rocker at 4 °C. After wash-
ing, blots were incubated for 1 h at room temperature with
secondary Abs: InfraRedDye-680 goat anti-mouse Ab (1:25000,
LI-COR Biosciences; Lincoln, NE) and IRD-800 goat anti-rab-
bit Ab (1:15000, LI-COR). The immunodetected proteins were
visualized by an Odyssey IR-imaging system (LI-COR).
Imaging and Image Analysis—Images were acquired on a
laser scanning confocal microscope (FluoView 1000; Olympus;
Center Valley, PA) with a 60 oil immersion lens, NA 1.42. At
least 200 cells were examined for each condition. Fiji software
was used to measure cell fluorescence and calculate the cor-
rected total cell fluorescence with correction for background
fluorescence. Blot images acquired from the Odyssey IR-imag-
ing system were analyzed using Odyssey Application Software
v.2.1 (LI-COR).
Statistical Analysis—Significance was tested by one-way or
two-way analysis of variance using the GraphPad Prism 5.01
program (GraphPad Software). One-way and two-way analysis
of variance was followed, respectively, by the Newman-Keuls
and Bonferroni multiple comparison test. Differences were
considered significant for p  0.05. Half-lives were calculated
using nonlinear regression and one-phase decay analysis.
Results
R-CRT Accumulation Results from Proteasomal Inhibition—
Arginylation is considered a primary destabilizing residue
according to the N-end rule for targeting proteins to protea-
somal degradation (19). To evaluate the role of arginylation in
removal of intracellular R-CRT, we incubated NIH 3T3 cells in
the presence of a potent reversible proteasome inhibitor
(MG132) and measured the cellular content of endogenous
cytoplasmic R-CRT by immunofluorescence at intervals using
anti-R-CRT Ab. This antibody specifically recognizes endoge-
nous R-CRT (7). After 1 h of MG132 treatment, the R-CRT
level was twice as high as that of control (non-treated) cells (p
0.001) (Fig. 1, A and B). After 2 h of treatment, the level was
slightly (p 0.05) higher than that at 1 h (Fig. 1,A andB). There
was a possibility that these findings resulted from inhibition of
cysteine protease by MG132 (31). We, therefore, performed
similar studies with lactacystin, an irreversible specific protea-
some inhibitor that does not affect cysteine proteases (32), and
obtained similar results (Fig. 2).
MG132 inhibits proteasomal degradation and also leads to a
heat-shock response that induces expression of ER chaperones
(33). Whether MG132 promotes retrotranslocation of ER pro-
teins is unknown. The increase of R-CRT after proteasome
inhibition could, therefore, be due to either increased CRT syn-
thesis or retrotranslocation. Our subsequent experiments were
designed to distinguish between these two possibilities.
We showed previously that R-CRT content increases when
cells are treated with an ER stressor (Tg) (7, 12). To determine
whether such an R-CRT increase is affected by proteasomal
inhibition, NIH-3T3 cells were treated with Tg in the presence
and absence ofMG132. R-CRT level in the Tg-treated cells was
increased to a similar degree regardless of MG132 treatment
(Fig. 1, C andD). However, when Tg was removed after 20 min
Proteasomal Degradation of Arginylated Calreticulin
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of treatment, the increased R-CRT level wasmaintained only in
cells treated withMG132 for 40 or 60min (Fig. 1,C andD). The
R-CRT level resulting from treatment with Tg alone was not
increased by the addition of MG132 (Fig. 1D: 20 Tg, white
versus black bar), indicating that MG132 did not activate CRT
retrotranslocation. The sustained increase of R-CRT in the
presence of MG132 after Tg removal was, therefore, due to
impaired proteasomal degradation. Because cyt-CRT accumu-
lation results from retrotranslocation of stored ER-CRT, it is
not possible to evaluate CRT degradation by using a protein
synthesis inhibitor to block CRT synthesis. Taken together,
these findings suggest that CRT is arginylated after retrotrans-
location from the ER to the cytoplasm (7, 12), and R-CRT is
then removed by the proteasomal degradation system.
Cyt-CRT Is Degraded Rapidly by Proteasomes in an Argi-
nylation-independent Manner—To determine whether arginyla-
tion of CRT is required for its proteasomal degradation, we
evaluated CRT degradation under conditions that precluded
N-terminal arginylation and analyzed proteasomal degradation
of CRT, R-CRT, and a non-arginylatable CRT (E1V-CRT)
expressed directly in the cytoplasm. Stable CHO cell lines
expressing three chimeric proteins (Ub-CRT-EGFP, Ub-R-
CRT-EGFP, Ub-E1V-CRT-EGFP) were used. Cleavage of the
Ub moiety by cellular C-terminal hydrolases was confirmed by
Western blotting (Fig. 3). Under immunofluorescence micros-
FIGURE 1. Proteasome inhibition in NIH 3T3 cells results in R-CRT accumulation in SGs. A, NIH 3T3 cells were incubated with MG132 (10M) for 1 and 2 h
(control: 0 h treatment). B, quantification of fluorescence intensity in immunofluorescence (A). Data are shown as themean S.E. *, p 0.05; ***, p 0.001 for
comparison with control. C, cells incubated in the absence or presence of MG132 (10M) and treated with Tg (2M) for 20min (20 TG) were analyzed 40 and
60 min after Tg removal (40 Post-TG and 60 Post-TG). D, quantification of fluorescence intensity in immunofluorescence data (C). The corrected total cell
fluorescencewas expressed as fold change value relative to control (0 h). Data are shown as themean S.E. ***, p 0.001 for intragroup comparison; i.e. black
bar versuswhite barwithin each of the four experimental groups. ###, p 0.001 for intergroup comparisonwith control (0 h) group; i.e. whiteor black barof 20
TG, 40 Post-TG, or 60 Post-TG group versus the corresponding bar of the control group. Results shown are representative of 200 cells from at least three
separate experiments for each condition. Scale bars, 20m.N.S., not significant. Cells were analyzed by double immunofluorescence using anti-R-CRT and SG
marker anti-TIA-1pAbs. Co-localizationof proteinswasmonitoredby confocalmicroscopy. SG formationwasobserveduponMG132 treatment, andR-CRTwas
found to be co-localized with SGs as shown by yellow pseudo-color in the merge images.
FIGURE 2.R-CRT accumulation in the presence of lactacystin. A, NIH 3T3
cells were incubated with 10 M lactacystin (LACTA) for 1 or 2 h (CONTROL:
0 h). Cells were analyzed by immunofluorescence using anti-R-CRT pAb. B,
quantification of fluorescence intensity in immunofluorescence data (A).
Corrected total cell fluorescence was expressed as -fold change value rel-
ative to control. Results shown are representative of 200 cells from at least
three separate experiments for each condition. Scale bar, 10 m. Data are
shown as the mean  S.E. *, p  0.05; ***, p  0.001 for comparison with
control.
FIGURE 3. Cytoplasmic expression of CRT. CHO cells transfected with Ub-
CRT-EGFP were incubated with MG132 (10 M) for 18 h. Cell lysates were
immunoprecipitated (IP) with anti-GFP Ab followed by immunoblotting (WB)
with anti-GFP. Polypeptides with sizes corresponding to the cleaved product
anduncleavedprecursor are indicated. Aband corresponding to theUb-CRT-
EGFP precursor was detected only in the treated cells after prolonged expo-
sure of the blots.
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copy, stably transfected cells showed EGFP fluorescence levels
slightly higher than the autofluorescence of nontransfected
cells, most likely because of rapid degradation of the expressed
proteins (Fig. 4,A–C). In cells treatedwithMG132,CRT-EGFP,
R-CRT-EGFP, and E1V-CRT-EGFP, levels increased at differ-
ent times (Fig. 4D). Immunocytochemical analysis (with an
anti-R-CRT Ab) of R-CRT-EGFP- and CRT-EGFP-transfected
cells treated with MG132 revealed similar accumulations of
R-CRT (Fig. 4E). In contrast, R-CRT was not detected in E1V-
CRT-EGFP-transfected cells, consistent with the presumed
inability of N-terminal Val to incorporate Arg (Fig. 4, C–E).
Although all three variants showed CRT accumulation in the
presence of MG132, Western blotting with anti-GFP Ab
revealed differences in their accumulation rates (Fig. 4F). An
increase of R-CRT-EGFP expression was observed after 2 h of
MG132 treatment, whereas cells expressing non-arginylatable
E1V-CRT-EGFPor arginylatableCRT-EGFP required 4 and 6 h
of MG132 treatment, respectively (Fig. 4F). In CRT-EGFP-ex-
pressing cells treated with MG132, protein accumulation was
detectedwith anti-GFP at essentially the same time that R-CRT
accumulation was detected by Western blotting with anti-R-
CRT Ab (Fig. 4F). Taken together, these findings indicate that
proteasome inhibition results in accumulation of R-CRT-
EGFP, CRT-EGFP, and E1V-CRT-EGFP and suggested that (i)
CRT arginylation is not required for its degradation, and (ii)
R-CRT-EGFP and E1V-CRT-EGFP are less susceptible to pro-
teasome degradation than is CRT-EGFP.
Effect of the N-terminal Amino Acid on CRT Half-life—The
observed accumulation of CRT-EGFP, R-CRT-EGFP, and E1V-
CRT-EGFP after MG132 treatment could be explained by dif-
ferential rates of synthesis (34). To evaluate this possibility, we
determined the half-life of each protein in the presence of the
protein synthesis inhibitor CHX. Stably transfected cells as
described in the preceding sectionwere incubatedwithMG132
to accumulate the corresponding protein (CRT-EGFP, R-CRT-
EGFP, E1V-CRT-EGFP),MG132was removed, cells were incu-
bated furtherwithCHX, andEGFP clearanceswere determined
at various times byWestern blotting (Fig. 5A). Clearance was
more pronounced for CRT-EGFP than for R-CRT-EGFP or
E1V-CRT-EGFP (Fig. 5, A and C). No changes in clearance
were observed when cells were incubated with CHX in the
presence of MG132 (Fig. 5, B and D). Half-lives in the pres-
ence of CHX were1.3 h for the mixture of CRT-EGFP and
R-CRT-EGFP present in CRT-EGFP cells, 0.7 h for the
non-arginylated CRT-EGFP, 2.0 h for R-CRT-EGFP, and
4.8 h for E1V-CRT-EGFP (Fig. 5E); i.e. the half-life of non-
arginylated CRT-EGFP was 65% shorter than that of R-CRT-
EGFP and 85% shorter than that of E1V-CRT-EGFP. The
half-life of R-CRT from CRT-EGFP and R-CRT-EGFP, as
determined using anti-R-CRT antibody, was2.0 h (Fig. 5F),
a similar value than that obtained employing anti-GFP anti-
body (Fig. 5, C and E).
MG132 has been reported to induce apoptosis in some cases
(35). It is, therefore, conceivable that this inhibitor affects CRT
levels indirectly via some apoptosis-related mechanism.
To test this possibility, we culturedCHOcells expressing CRT-
EGFP, R-CRT-EGFP, or E1V-CRT-EGFP in the presence of
MG132 and analyzed cell viability by the colorimetric resazurin
assay. No changes were observed in viability at least up to 24 h of
MG132 treatment (Fig. 6A). Moreover, no significant increase in
cell death was detected by flow cytometry of propidium iodide-
stained cells at the times studied (Fig. 6B).
These findings demonstrate that CRT-EGFP, R-CRT-EGFP,
and E1V-CRT-EGFP undergo proteasomal degradation and
that arginylation of CRT is not required for its proteasomal
degradation. Because CRT-EGFP is arginylated by Ate1 and
someCRT-EGFP remains arginylation-free (Fig. 7), the half-life
of the mixture of non-arginylated CRT-EGFP and R-CRT-
FIGURE 4. cyt-CRT with various N termini are rapidly degraded by proteasomes. Stably transfected cells expressing CRT-EGFP (A), R-CRT-EGFP (B), or
E1V-CRT-EGFP (C) were incubatedwithMG132 (10M) for various durations and analyzed by triple immunofluorescence for detection of EGFP emission using
anti-R-CRT pAb and DAPI. Merge images for EGFP emission and anti-R-CRT Ab are shown in the corresponding panels. Scale bars, 20 m. Quantification of
fluorescence intensity in immunofluorescencedataof EGFPemission (D) or anti-R-CRTAb (E)was expressed in relative fluorescenceunits (RFU). Data are shown
as themean S.E. ***, p 0.001 for intragroup comparison; i.e. gray (or black) bar versuswhite barwithin each of the three experimental groups. ###, p 0.001
for intergroup comparison with 0 h group; i.e. white, gray, or black bar of 6-h or 12-h group versus the corresponding bar of the 0 h group. N.S., not significant.
Results are representative of 180 cells from at least three separate experiments for each condition. F, immunoblotting analysis of CRT-EGFP, R-CRT-EGFP, and
E1V-CRT-EGFP content for the indicated MG132 incubation times.
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EGFP is presumed to lie between that of R-CRT-EGFP and
E1V-CRT-EGFP. However, the degradation of the mixture of
non-arginylated CRT-EGFP and R-CRT-EGFP is faster than
that of R-CRT-EGFP or E1V-CRT-EGFP (Fig. 5E), indicating
that non-arginylated CRT-EGFP should be degraded more
efficiently.
Degradation of R-CRT and CRT in Cells Lacking Ate1—The
mutation introduced into CRT for preparation of E1V-CRT
may, in addition to preventing its arginylation, induce confor-
mational changes in the protein. To test this possibility, we
examined CRT-EGFP degradation in ATE1/ cells (9, 36).
These cells were transfected with Ub-CRT-EGFP or Ub-R-
CRT-EGFP and treated withMG132 for 18 h to allow cytoplas-
mic accumulation of CRT-EGFP or R-CRT-EGFP. MG132 was
removed, cells were cultured with CHX for 2 h, and protein
expressionwas analyzed byWestern blotting. In agreementwith
the results shown in Fig. 5, CRT-EGFP and R-CRT-EGFP were
decreased by treatment with CHX alone but unaffected by treat-
ment with CHXplusMG132 (Fig. 8,A andB). The CHX-induced
decrease was significantly smaller (40%; p  0.05) for R-CRT-
EGFP- versus CRT-EGFP-expressing cells (Fig. 8B). The simplest
interpretationof these findings is that arginylationofCRT impairs
its degradation and that different proteasomal pathways are
involved in the degradation of CRT versus R-CRT.
FIGURE 5. Non-arginylated CRT has a shorter half-life than arginylated CRT and non-arginylatable CRT. Stably transfected cells expressing CRT-EGFP,
R-CRT-EGFP, or E1V-CRT-EGFP were treated with MG132 to cause accumulation of these proteins. MG132 was removed, cells were incubated in the presence
of CHX (A) or CHXMG132 (B), and contents of CRT-EGFP, R-CRT-EGFP, and E1V-CRT-EGFPwere analyzed at the indicated incubation times by immunoblotting
with anti-GFP, anti-R-CRT, and anti--actin Abs. The Western blots shown are representative of seven independent experiments. C and D, intensities of EGFP
bands relative to -actin were measured, expressed as arbitrary units (A.U.) and plotted as a fraction of band intensity at 2 h. To make possible determination
of half-lives in the linear range, we did not consider the initial band intensity (0 h), because this signal is saturated and cannot be used for half-life calculation.
E, half-lives were determined in the linear range (2 h through 7 h as shown in A–D). Estimated half-lives of R-CRT-EGFP and E1V-CRT-EGFP were
extrapolated by non-linear regression from a one-phase exponential decay curve fitted to the data points in C. Estimated half-life of non-arginylated
CRT-EGFP was calculated by non-linear regression from a two-phase exponential decay curve fitted to the data points of the CRT/R-CRTmixture present
in CRT-EGFP cells, in C. The constraints used for the two-phase exponential decay curve were: (i) half-life of R-CRT (2 h); (ii) percentage of initial
non-arginylated CRT-EGFP (40%; Fig. 7). Values shown are the mean S.E. of seven independent experiments. *, p 0.05; ***, p 0.001. F, intensities
of R-CRT bands relative to -actin from CRT-EGFP and R-CRT-EGFP cells in the presence of CHX were measured, expressed as arbitrary units (A.U.), and
plotted as a fraction of band intensity at 2 h. The estimated half-lives of R-CRT from CRT-EGFP and R-CRT-EGFP cells are the same and consistent with
those calculated for R-CRT-EGFP cells using anti-GFP Ab (2 h).
Proteasomal Degradation of Arginylated Calreticulin
16408 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 290•NUMBER 26•JUNE 26, 2015
 at Carleton U
niv - O
CU
L on July 1, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
To rule out the possibility that EGFP contributes to the deg-
radation of these variants, ATE1/ cells were transfected with
Ub-CRT-FLAG or Ub-R-CRT-FLAG and treated with MG132
for 12 h to allow cytoplasmic accumulation of CRT-FLAG or
R-CRT-FLAG. MG132 was removed, cells were cultured with
CHX for 1 or 2 h, and protein level was analyzed byWestern blot-
ting. Results for proteins fused with FLAG versus EGFP at the C
terminusof isoformswere similar (Fig. 9,A–D), indicating that the
CRT sequence encloses the signal for degradation and that the
signal is not affected by EGFP fusion at the C terminus.
R-CRT-EGFP Is Degraded by the Ub Proteasome System—
The finding that arginylatable CRT-EGFP is degraded more
rapidly than areR-CRT-EGFPor E1V-CRT-EGFP suggests that
the isoforms are subject to different proteasomal mechanisms.
We, therefore, examined the possible involvement of the Ub-
proteasome system in these differences. CHO cells were co-
transfected to expressHA epitope-taggedUb and either R-CRT
or E1V-CRT, and ubiquitination status was examined. Six
hours after co-transfection, cells were incubated with MG132
for 18 h to allow accumulation of Ub conjugates. R-CRT-EGFP
and E1V-CRT-EGFP were then immunoprecipitated from
lysed cells with anti-GFP Ab (Fig. 10A) and analyzed by West-
ern blottingwith anti-HAAb.HA-Ub conjugateswere detected
only for R-CRT (Fig. 10B), suggesting that arginylation is nec-
essary for an efficient ubiquitination of R-CRT and that non-
arginylatable CRT is degraded via a Ub-independent protea-
somal pathway.
Why Does Arginylation of CRT Not Follow the N-end Rule?—
According to the N-end rule, Arg is a primary destabilizing
residue that targets proteins for degradation by the Ub-protea-
FIGURE 6.Viability and apoptosis control uponMG132 treatment. A, viability of cells expressing R-CRT-EGFP, CRT-EGFP, or E1V-CRT-EGFP, assessed by the
reduction of resazurin at various intervals (12, 18, 21, 24 h) of treatment with 10 M MG-132. Data are the means  S.D. (n 	 6). All comparisons were not
significant at p
 0.05. B, flow cytometry histograms of cells stably expressing CRT-EGFP or R-CRT-EGFP stainedwith propidium iodide at various intervals (12,
18, 24 h) of treatmentwith 10MMG132. Values of 100%correspond to 50,000 cells. The data shownare themeans of three independent experiments.MG132
treatment for 24 h with a dose of 10M did not induce apoptosis. The slight induction of apoptosis in R-CRT-EGFP cells at 24 h of MG132 treatment may have
been due to accumulation of pro-apoptotic R-CRT in the plasma membrane (11).
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some system (19, 20). However, we found that the half-life of
CRT, which has a Glu residue at its N terminus, is shorter than
that of R-CRT. What is the cause of the higher half-life of
R-CRT?We demonstrated previously that R-CRT but not CRT
is recruited to SGs and that R-CRTmoves to the plasma mem-
brane in response to stress, acting as a pro-apoptotic signal (11).
Arginylation may, therefore, protect CRT from proteasomal
degradation under stress conditions by altering its metabolic
fate. The dimerization of R-CRT is of a higher magnitude than
that of CRT. Disulfide-bridged dimerization is essential for
scaffolding of larger SGs under heat shock (13).
The above findings suggest that dimerization of R-CRT is
anotherway to avoid proteasomal degradation. To evaluate this
possibility, we examined R-CRT accumulation in cells incu-
bated in the absence versus presence of (i) MG132 and (ii)
dimerization conditions. Because homodimers of CRT are
formed under non-reducing conditions by exposure of free SH-
Cys-146 (13, 37, 38), we generated aCRTmutant (C146A-CRT-
EGFP) that cannot dimerize. CRT knock-out fibroblasts
(CRT/) were transfected with C146A-CRT-EGFP or WT
CRT (WT-CRT-EGFP) that are directed to the ER. Transfected
cells were analyzed by immunocytochemistry using anti-R-
CRTAb (Fig. 11). Cells transfected with C146A-CRT and incu-
bated in the absence ofMG132 showedR-CRT levels 25% lower
than those of cells transfected withWT-CRT-EGFP (Fig. 11,A,
B, and E). R-CRT levels in MG132-treated cells were 2-fold
higher than those in MG132-nontreated cells (Fig. 11E),
regardless of the dimerization capability of the transfected pro-
tein. This finding is consistentwith the idea that R-C146A-CRT
remains in a monomeric form susceptible to proteasomal deg-
radation. Similar results were obtained when NIH-3T3 cells
were cultured in the presence of dithiothreitol to induce disul-
fide bridge breakage, and R-CRT levels were determined in the
presence versus absence of MG132 (data not shown). These
findings indicate that R-CRT dimerization prevents its protea-
somal degradation and accounts for its reduced turnover rate
(Fig. 5).
In summary, the dimerization capability of different CRT
isoforms is correlated with their susceptibility to proteasomal
degradation. In contrast to the N-end rule, which predicts a
longer half-life for CRT than for R-CRT, our results indicate
that CRT arginylation is responsible for the longer half-life of
R-CRT, even though this isoform is the substrate of the Ub-
proteasome system.
Discussion
The present study was focused on the degradation mecha-
nismwhereby cells modulate cytoplasmic CRT and R-CRT lev-
els. Our previous studies have shown that R-CRT is directed to
SG under stress conditions in which Ca2 levels are decreased
(7, 12, 39) and that R-CRT may reach the plasma membrane if
the stress persists (11). It was suggested that CRT from plasma
membrane is degraded in the lysosome pathway (40). However,
the degradation pathway of internal CRT is unclear, and that of
R-CRT is completely unknown. Afshar et al. (24) claimed that
cyt-CRT is not a proteasomal substrate because it did not detect
ubiquitinated cyt-CRT in cells. On the other hand, Labriola et
al. (25) suggested that CRT is degraded in the cytosol by pro-
teasome because, after exposure of cells to an inhibitor of ER
Ca2-ATPase, cyt-CRT level was reduced by CHX treatment
and increased byMG132 treatment. Our present findings indi-
cate that both CRT and R-CRT are proteasomal substrates,
although the degradation rate of R-CRT is lower than that of
CRT (Figs. 4, 5, 8, and 9). The same trend was observed for the
endogenous protein (Figs. 1 and 2), indicating that R-CRT half-
life is not affected by other PTMs onCRT after passage through
the ER.
R-CRT accumulation in cells is a consequence of proteasome
inhibition (Figs. 1 and 2). Such accumulation occurs primarily
during the first hour of MG132 exposure, suggesting that cyt-
CRT is regulated at the retrotranslocation level. Our findings
show clearly that the accumulation is due to blocking of protea-
somal activity rather than to increased retrotranslocation or
CRT synthesis (Fig. 1, C and D), consistent with previous find-
ings that CRT retrotranslocation is independent of protea-
somal activity (24). ER stress does not appear to promote
R-CRT accumulation, because MG132 treatment of cells pro-
duced only a slight accumulation of reporter cytoplasmic sub-
strates (41).
FIGURE 7. Proportion of R-CRT in CRT-EGFP cells. A, stably transfected cells
expressing CRT-EGFP and R-CRT-EGFP were treated with MG132 (10 M) for
12 h to cause accumulation of these proteins. MG132was removed, and cells
were washed 4 times, cultured for 1 h to allow diffusion of the inhibitor,
washedagain, and incubated for 2h inpresenceofCHX.CRT-EGFPandR-CRT-
EGFP content was analyzed by immunoblotting using anti-GFP, anti-R-CRT,
and anti--actin Abs. B, the fraction of R-CRT-EGFP present in CRT-EGFP cells
was obtained from the relations between the intensities of EGFP and R-CRT
bands and plotted as a percent of the relation between EGFP and R-CRT
bands intensities in R-CRT-EGFP cells. The relation between the intensities of
EGFP and R-CRT bands in R-CRT-EGFP cells reflects the different sensitivity of
anti-GFP and anti-R-CRT Abs and corresponds to 100% of R-CRT-EGFP. The
estimatednon-arginylatedCRT-EGFP inCRT-EGFP cellswas 40%, correspond-
ing to the point 2 h in the half-life determination experiments (Fig. 5). Data
represent the mean S.E. of seven independent experiments.
FIGURE 8. Arginylation-independent proteasomal degradation of CRT.
Ate1/ cells were transfected with Ub-CRT-EGFP or Ub-R-CRT-EGFP and
treated with MG132 for 18 h to cause accumulation of CRT-EGFP or R-CRT-
EGFP. MG132 was removed, and cells were incubated in the absence or pres-
ence of CHXor CHXMG132 for 2 h.A, immunoblotting. B, intensities of EGFP
bands relative to-actinweremeasured andplotted as apercentageof initial
band intensity (control: 0 h). Data are shown as the mean  S.E. of three
independent experiments. *, p 0.05.
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Arginylatable CRT, R-CRT isoform, and non-arginylatable
mutant E1V-CRT expressed in cytoplasm had very different
half-lives: longest for E1V-CRT (4.8 h), intermediate for
R-CRT (2.0 h), and shortest for CRT (0.7 h) (Fig. 5). R-CRT
was ubiquitinated, but E1V-CRT was not (Fig. 10). These find-
ings, taken together, could be interpreted as following the
N-end rule, in that arginylation of proteins facilitated their rec-
ognition by E3 Ub ligases and was followed by proteasomal
degradation (19, 20). However, ubiquitination in this case did
not confer a shorter half-life to R-CRT as predicted by the
N-end rule. Rather, our findings are consistent with protea-
somal degradation of CRT by two distinct mechanisms, one
Ub-dependent and the other Ub-independent. Similar
results have been obtained for other proteins (e.g. ornithine
decarboxylase, c-FOS, p21Waf1/Cip1) that undergo protea-
somal degradation in the absence of Ub modification (21,
42). However, it cannot be discarded that both isoforms of
CRT could be degraded by the ubiquitin proteasome system
with a difference in the efficiency of their ubiquitination.
Further studies of the ubiquitination of R-CRT will be useful
to elucidate the detailed mechanism of proteasomal target-
ing for its degradation.
The proteasomal pathway involves several coexisting types
of proteasomes (26S, 20S, immunoproteasome, etc.) (43). 26S
proteasomes, which account for 15% of total proteasomes,
degrade natively folded and functional proteins in a primarily
Ub-dependent manner (43). In contrast, 20S proteasomes,
which account for 40% of total proteasomes, degrade dam-
aged/misfolded proteins in a Ub-independent manner (43).
Different proteasome complexesmay, therefore, be responsible
for the strikingly different half-lives of CRT, R-CRT, and E1V-
CRT. Ubiquitinated R-CRT is most likely degraded by 26S pro-
teasomes, whereas non-ubiquitinatable E1V-CRT is degraded
by some other type. Because CRT can be arginylated by cellular
Ate1, it may be degraded bymore than one type of proteasomal
complex, accounting for its lower half-life in cells that express
CRT-EGFP. In Ate1/ cells expressing CRT or R-CRT, deg-
radation of the two proteins is related to differences in half-life
similar to those observed in the other experimental systems
used (Figs. 8 and 9). CRT expressed in Ate1/ cells remains
FIGURE 9. EGFP does not contribute to proteasomal degradation of CRT fusion proteins. Ate1/ cells were transfected with Ub-CRT-FLAG or Ub-R-CRT-
FLAG and treated with MG132 for 12 h to cause accumulation of CRT-FLAG or R-CRT-FLAG. MG132 was removed, cells were incubated in the absence or
presence of CHX (A) or CHXMG132 (B) for 1 or 2 h, and proteins were separated and immunoblotted. C, intensities of FLAG bands relative to -actin were
measured and plotted as a percentage of initial band intensity (control: 0 h). Data are shown as themean S.E. of three independent experiments. *, p 0.05;
**, p 0.01.
FIGURE 10. R-CRT is ubiquitinated. CHO cells were co-transfected with HA
epitope-tagged Ub and Ub-R-CRT-EGFP or Ub-E1V-CRT-EGFP. Control cells
were transfectedwithHAepitope-taggedUbaloneorwith EGFP. Transfected
cells were treated with MG132 for 18 h to cause accumulation of Ub conju-
gates, R-CRT-EGFP, or E1V-CRT-EGFP. Cell lysates were immunoprecipitated
with anti-GFP Ab followed by immunoblotting (WB) with anti-GFP (A) and
anti-HA (B) Abs. Lanes 3,6,9, and12, immunoprecipitatedproteins (IP); lanes 1,
4, 7, and 10, total cell lysate (Input): lanes 2, 4, 8, and 11, flow-through
(Unbound).
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arginylation-free, similarly to E1V-CRT expressed in stably
transfected CHO cells. However, the half-life of the E1V-CRT
isoform is longer than that of R-CRT (Fig. 5), suggesting that
CRT turnover is altered by point mutation of the Glu residue.
In regard to the molecular determinants that target CRT to
proteasomal degradation, we hypothesize that other PTMs
such as phosphorylation (44) or the presence of PEST
sequences in theCRTprimary structure could be involved. Pre-
vious reports suggest that intrinsically disordered regions,
unfolding, and oxidative damage are potential determinants of
proteasomal degradation (21, 45). Further studies are needed to
clarify the molecular contributions of such determinants to
CRT degradation.
Arginylation of CRT affects its subcellular localization (7,
11). We observed that proteasomal inhibition resulted in accu-
mulation of R-CRT in SGs (Fig. 1). Because only R-CRT is asso-
ciated with SGs (7), we presume that these structures interfere
with proteasomal degradation of R-CRT. Arginylation may
also promote molecular rearrangements of the cyt-CRT
population, e.g. by facilitating homodimer formation (13),
and thereby block proteasomal degradation (Fig. 11). Impor-
tant points remaining to be clarified are whether R-CRT is
protected from degradation because the dimerized form
cannot undergo polyubiquitination, or polyubiquitinated
R-CRT is protected from degradation by physical association
with stress granules.
FIGURE 11. R-CRT dimerization interferes with proteasomal degradation. CRT/ cells were transfected with WT-CRT-EGFP (A and C) or C146A-CRT-EGFP
(B and D) and incubated in the absence (A and B) or presence (C and D) of MG132 for 2 h. Scale bar, 10 m. Cells were analyzed as in Fig. 2. E, quantification of
fluorescence intensity. Corrected total cell fluorescence is expressed as -fold change value relative to control (0 h). Data are shown as themean S.E. ***, p
0.001 for intragroup comparison; i.e. black bar versuswhite barwithin CRT-EGFP or C146A-CRT-EGFP group. ###, p 0.001 for intergroup comparison; i.e. white
or black bar of C146A-CRT-EGFP group versus the corresponding bar of CRT-EGFP group. Results are representative of 150 cells from at least three separate
experiments for each condition.
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Previous studies indicate that proteins such as C/EBP are
stabilized by homodimer or heterodimer formation (46). The
longer half-life of R-CRT (Fig. 12) may result from any of the
mechanisms mentioned above (ubiquitination, dimer forma-
tion, association with SGs, accumulation at the plasma mem-
brane). Once CRT leaves the ER, it must be removed quickly
from the cytoplasm because its continued presence would alter
Ca2 homeostasis so as to reduce cell survival. CRT is involved
in a variety of injury processes including cell stress, apoptosis,
and phagocytosis. CRT must be stabilized in the cytoplasm in
order to play its normal role in these processes. Arginylation of
CRT is important for such stabilization as well as for the pro-
cesses of SG formation, plasma membrane localization, and
pro-apoptotic signaling. The regulation ofCRT levels in various
subcellular structures depends on control of not only its syn-
thesis (47) but also its degradation.
The present findings demonstrate cross-talk among the
events of CRT retrotranslocation, post-translational arginyla-
tion, ubiquitination, and homodimer formation. Future studies
will more fully elucidate the cross-talk among PTMs that mod-
ulate the fate of CRTs.
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